Percutaneous endoscopically assisted transenteric full-thickness gastric biopsy: initial experience in humans - 11/08/11
Résumé |
Background |
GI neuromuscular diseases (GINMD) can cause severe dysmotility and symptoms. Full-thickness biopsy specimens may help diagnose these disorders histologically.
Objective |
To assess a novel percutaneous endoscopically assisted transenteric (PEATE) biopsy method for obtaining full-thickness gastric tissue in patients with suspected GINMD.
Design |
Prospective proof-of-concept case series.
Setting |
Tertiary care gastroenterology unit.
Patients |
Ten patients (8 women, mean [standard deviation] age 43 [10] years) with gastroparesis-like symptoms (mean [standard deviation] gastroparesis cardinal symptom index 3.28 [1.46] out of 5) and/or clinical findings suggestive of a gastric GINMD.
Interventions |
All patients underwent PEATE biopsy during standard gastroscopy as an outpatient procedure. Tissue was stained for histology and immunohistochemistry of gut wall elements. Interstitial cells of Cajal (ICC) counts were compared with archived normal gastric tissue from control gastrectomies.
Main Outcome Measurements |
Biopsy success, complications, histopathological findings according to the London Classification of GINMD.
Results |
Full-thickness antral tissue suitable for analysis was obtained in 9 in 10 patients (90%). PEATE biopsy was well tolerated by all patients without complications. Histology suggested GINMD in 4 of 9 cases (44%), with possible degenerative leiomyopathy in 2, probable inflammatory leiomyopathy in 1, and abnormal ICC networks (>50% reduction in ICC counts) in 1 patient.
Limitations |
PEATE biopsy specimen size is smaller than a standard laparoscopic full-thickness biopsy.
Conclusions |
PEATE full-thickness gastric biopsy is a simple and safe method of assessing histopathological abnormalities in gastric GINMD without the need for laparoscopy or general anesthesia.
Le texte complet de cet article est disponible en PDF.Abbreviations : DGP, ENS, GINMD, GP, ICC, IGP, PEATE, SDAP
Plan
| DISCLOSURE: Dr Andrews has filed a provisional patent for the PEATE procedure in the United States. The other authors disclosed no financial relationships relevant to this publication. Dr Andrews was funded in part by Calgary Laboratory Services R&D grant RE7133. |
|
| If you would like to chat with an author of this article, you may contact Dr Andrews at candrews@ucalgary.ca. |
Vol 73 - N° 5
P. 949-954 - mai 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
